{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:30:25Z","timestamp":1781152225419,"version":"3.54.1"},"reference-count":28,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2022.0364","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T09:08:03Z","timestamp":1673428083000},"source":"Crossref","is-referenced-by-count":1,"title":["Skin cancer screening and medical treatment intensity in patients with malignant melanoma and non-melanocytic skin cancer"],"prefix":"10.3238","author":[{"given":"Katrin","family":"Schuldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Trocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard","family":"Lax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nonnemacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"G\u00fcnster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Pahmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Speckemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Neusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"10.3238\/arztebl.m2022.0364_ref1","unstructured":"Gemeinsamer Bundesausschuss: Richtlinie des Gemeinsamen Bundesausschusses \u00fcber die Fr\u00fcherkennung von Krebserkrankungen (Krebsfr\u00fcherkennungs-Richtlinie\/KFE-RL]. www.g-ba.de\/downloads\/62–492–2238\/KFE-RL_2020–06–18_iK-2020–08–28.pdf (last accessed on 1 December 2021)."},{"key":"10.3238\/arztebl.m2022.0364_ref2","doi-asserted-by":"crossref","unstructured":"Breitbart E, Waldmann A, Nolte S, et al.: Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012; 66: 201–11.","DOI":"10.1016\/j.jaad.2010.11.016"},{"key":"10.3238\/arztebl.m2022.0364_ref3","doi-asserted-by":"crossref","unstructured":"Nolte S, Waldmann A, Capellaro M, et al.: Das SCREEN Projekt – Ergebnisse des populationsbezogenen Pilotprojektes zum Hautkrebsscreening in Schleswig-Holstein. Gesundheitswesen 2010; 72: V1.","DOI":"10.1055\/s-0030-1266161"},{"key":"10.3238\/arztebl.m2022.0364_ref4","unstructured":"BQS Institut f\u00fcr Qualit\u00e4t und Patientensicherheit GmbH: Evaluation der Screeninguntersuchungen auf Hautkrebs gem\u00e4\u00df Krebsfr\u00fcherkennungs-Richtlinie des Gemeinsamen Bundesausschusses. Abschlussbericht der Jahre 2014–2018. 2020."},{"key":"10.3238\/arztebl.m2022.0364_ref5","unstructured":"Egidi G, Chenot J: Empfehlungen zum Hautkrebsscreening in der S3-Leitlinie „Pr\u00e4vention von Hautkrebs“-Kritik der DEGAM Teil 1. Z Allg Med 2015; 91: 117–20."},{"key":"10.3238\/arztebl.m2022.0364_ref6","unstructured":"World Health Organization: Screening programmes: a short guide. Copenhagen: World Health Organization; 2020."},{"key":"10.3238\/arztebl.m2022.0364_ref7","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen KJ: Melanoma screening. Dermatology 2017; 233: 410–1.","DOI":"10.1159\/000484948"},{"key":"10.3238\/arztebl.m2022.0364_ref8","doi-asserted-by":"crossref","unstructured":"Brun\u00dfen A, Eisemann N, H\u00fcbner J, Katalinic A: Aktuelle Evidenz zum Nutzen des Hautkrebs-Screenings In:G\u00fcnster C, Klauber J, Robra BP, Schmacke N, Schmuker C (eds.]: Versorgungs-Report-Fr\u00fcherkennung. MWV Berlin 2019; 191–207.","DOI":"10.32745\/9783954664023-13"},{"key":"10.3238\/arztebl.m2022.0364_ref9","doi-asserted-by":"crossref","unstructured":"Speckemeier C, Pahmeier K, Trocchi P, et al.: One-year follow-up healthcare costs of patients diagnosed with skin cancer in Germany: a claims data analysis. BMC Health Serv Res 2022; 22: 771.","DOI":"10.1186\/s12913-022-08141-9"},{"key":"10.3238\/arztebl.m2022.0364_ref10","doi-asserted-by":"crossref","unstructured":"Stang A, Schuldt K, Trocchi P, et al.: The impossibility of mortality evaluation of skin cancer screening in Germany based on health insurance data: a case-control study. Eur J Cancer 2022; 173: 52–8.","DOI":"10.1016\/j.ejca.2022.06.009"},{"key":"10.3238\/arztebl.m2022.0364_ref11","unstructured":"World Health Organization: The international statistical classification of diseases and related health problems, 10th revision. Geneva: World Health Organization; 1992."},{"key":"10.3238\/arztebl.m2022.0364_ref12","doi-asserted-by":"crossref","unstructured":"Elixhauser A, Steiner C, Harris D, Coffey R: Comorbidity measures for use with administrative data. Med Care 1998; 36: 8–27.","DOI":"10.1097\/00005650-199801000-00004"},{"key":"10.3238\/arztebl.m2022.0364_ref13","doi-asserted-by":"crossref","unstructured":"Boogaerts G, Loyd C, Zhang Y, Kennedy RE, Brown CJ: National norms for the Elixhauser and Charlson Comorbidity Indexes among hospitalized adults. J Gerontol A Biol Sci Med Sci 2022: glac087.","DOI":"10.1093\/gerona\/glac087"},{"key":"10.3238\/arztebl.m2022.0364_ref14","unstructured":"Statistisches Landesamt Baden-W\u00fcrttemberg: Entstehung, Verteilung und Verwendung des Bruttoinlandsprodukts in den L\u00e4ndern der Bundesrepublik Deutschland 1991–2020. www.statistikportal.de\/de\/veroeffentlichungen\/entstehung-verteilung-verwendung-des-bruttoinlandsprodukts (last accessed on 6 April 2022)."},{"key":"10.3238\/arztebl.m2022.0364_ref15","doi-asserted-by":"crossref","unstructured":"Autier P, Boniol M: Pitfalls in using case-control studies for the evaluation of the effectiveness of breast screening programmes. Eur J Cancer Prev 2013; 22: 391–7.","DOI":"10.1097\/CEJ.0b013e32835ccca4"},{"key":"10.3238\/arztebl.m2022.0364_ref16","doi-asserted-by":"crossref","unstructured":"Senore C, Riggi E, Armaroli P, et al.: Long-term follow-up of the Italian flexible sigmoidoscopy screening trial. Ann Intern Med 2022; 175: 36–45.","DOI":"10.7326\/M21-0977"},{"key":"10.3238\/arztebl.m2022.0364_ref17","doi-asserted-by":"crossref","unstructured":"Welch HG, Mazer BL, Adamson AS: The rapid rise in cutaneous melanoma diagnoses. N Engl J Med 2021; 384: 72–9.","DOI":"10.1056\/NEJMsb2019760"},{"key":"10.3238\/arztebl.m2022.0364_ref18","doi-asserted-by":"crossref","unstructured":"Zeissig S, Arndt V, Kraywinkel K: Beitr\u00e4ge der Epidemiologie bei der Sekund\u00e4rpr\u00e4vention von Krebserkrankungen. Onkologie 2020; 26: 393–401.","DOI":"10.1007\/s00761-020-00755-0"},{"key":"10.3238\/arztebl.m2022.0364_ref19","doi-asserted-by":"crossref","unstructured":"Stang A, Augustin M: Krebs-Screening-Programme: Methodische Grundlagen und erste Erfahrungen mit dem Hautkrebs-Screening. Onkologie 2011; 34 (Suppl 2): 2–4.","DOI":"10.1159\/000324826"},{"key":"10.3238\/arztebl.m2022.0364_ref20","doi-asserted-by":"crossref","unstructured":"Stang A, Ziegler S, B\u00fcchner U, Ziegler B, J\u00f6ckel KH, Ziegler V: Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs. diagnosis-based incidence approach. Int J Dermatol 2007; 46: 564–70.","DOI":"10.1111\/j.1365-4632.2006.03056.x"},{"key":"10.3238\/arztebl.m2022.0364_ref21","doi-asserted-by":"crossref","unstructured":"Eigentler T: Benefits of a nationwide population-based skin cancer screening programme-still a controversial debate. Br J Dermatol 2022; 186: 8–9.","DOI":"10.1111\/bjd.20709"},{"key":"10.3238\/arztebl.m2022.0364_ref22","doi-asserted-by":"crossref","unstructured":"Augustin M, Girbig G, Kis A, et al.: Station\u00e4re Versorgung von Hautkrankheiten in Deutschland: Multi-Source-Analyse zum aktuellen und zuk\u00fcnftigen Bedarf. JDDG 2021; 19: 25–54.","DOI":"10.1111\/ddg.14620_g"},{"key":"10.3238\/arztebl.m2022.0364_ref23","doi-asserted-by":"crossref","unstructured":"Krensel M, Andrees V, Mohr N, Hischke S: Costs of routine skin cancer screening in Germany: a claims data analysis. Clin Exp Dermatol 2021; 46: 842–50.","DOI":"10.1111\/ced.14550"},{"key":"10.3238\/arztebl.m2022.0364_ref24","doi-asserted-by":"crossref","unstructured":"Bartholom\u00e4us S, Siegert Y, Hense H, Heidinger O: Secure linking of data from population-based cancer registries with healthcare data to evaluate screening programs. Gesundheitswesen 2019; 82: 131–8.","DOI":"10.1055\/a-1031-9526"},{"key":"10.3238\/arztebl.m2022.0364_ref25","unstructured":"Zentrum f\u00fcr Krebsregisterdaten im Robert Koch-Institut: Datenbankabfrage mit Sch\u00e4tzung der Inzidenz, Pr\u00e4valenz und des \u00dcberlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten www.krebsdaten.de\/abfrage (last accessed on 16 March 2021)."},{"key":"10.3238\/arztebl.m2022.0364_ref26","doi-asserted-by":"crossref","unstructured":"Jaunzeme J, Eberhard S, Geyer S: [How „representative“ are SHI (statutory health insurance] data? Demographic and social differences and similarities between an SHI-insured population, the population of Lower Saxony, and that of the Federal Republic of Germany using the example of the AOK in Lower Saxony]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 447–54.","DOI":"10.1007\/s00103-012-1626-9"},{"key":"10.3238\/arztebl.m2022.0364_ref27","doi-asserted-by":"crossref","unstructured":"Pflugfelder A, Kochs C, Blum A, et al.: S3-Leitlinie „Diagnostik, Therapie und Nachsorge des Melanoms“. JDDG 2013; 11: 1–126.","DOI":"10.1111\/ddg.12113"},{"key":"10.3238\/arztebl.m2022.0364_ref28","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF]: S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut, Langversion 1.1. www.awmf.org\/uploads\/tx_szleitlinien\/032–022OLl_S3_Aktinische_Keratosen-Plattenepithelkarzinom-PEK_2020–04.pdf (last accessed on 1 February 2021)."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T09:09:05Z","timestamp":1673428145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":28,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2022.0364","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]}}}